secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001683168-24-000150
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products
-------------------------------------------------------------------------

- Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.
- Initial 2-year term auto-renewing; royalty on Net Sales (percentage redacted) due quarterly.
- Marketing through Sonoma's existing EU distribution network; NovaBay retains rights outside territories.
- NovaBay represents it owns the marks, but applications in EU are still pending as previously disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/0001683168-24-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer